Spanish (IBEX) Healthcare Sector Analysis

Date	Market Cap	Revenue	Earnings	PE
Sat, 22 Jan 2022	€19.1b	€7.9b	€932.5m	17x
Mon, 20 Dec 2021	€19.0b	€7.8b	€931.2m	16.9x
Wed, 17 Nov 2021	€19.8b	€7.8b	€911.9m	18.7x
Fri, 15 Oct 2021	€21.7b	€7.8b	€912.6m	19.3x
Sun, 12 Sep 2021	€22.0b	€7.8b	€912.6m	18.2x
Tue, 10 Aug 2021	€22.2b	€7.8b	€912.6m	18.3x
Mon, 03 May 2021	€22.8b	€7.7b	€876.2m	21.4x
Thu, 04 Feb 2021	€22.9b	€7.8b	€977.0m	23.4x
Sun, 08 Nov 2020	€21.1b	€7.9b	€1.0b	14.5x
Sat, 01 Aug 2020	€21.6b	€7.8b	€910.8m	18.2x
Tue, 05 May 2020	€24.8b	€7.7b	€1.0b	16.8x
Fri, 07 Feb 2020	€24.3b	€7.3b	€854.5m	21.8x
Thu, 31 Oct 2019	€23.8b	€7.1b	€747.4m	23.9x
Sun, 04 Aug 2019	€24.0b	€6.9b	€758.9m	20.2x
Wed, 08 May 2019	€20.6b	€6.6b	€734.9m	20.7x
Sat, 09 Feb 2019	€19.6b	€6.5b	€742.3m	21.5x


Medical Equipment	2.10%
Healthcare Services	-0.58%
Pharma	-2.16%
Biotech	-2.35%
Life Sciences	-6.35%

Company	Last Price	7D	1Y	Valuation
ALM Almirall	€10.92	1.8% +€34.2m	-5.4%	PS2.4x
PRM Prim	€14.55	2.1% +€5.2m	51.9%	PE18.3x
ORY Oryzon Genomics	€3.12	1.5% +€2.4m	-17.7%	PS16.9x
PHM Pharma Mar	€55.88	0.1% +€1.4m	-35.4%	PE16.6x
ADL ADL Bionatur Solutions	€0.47	2.4% +€501.7k	-32.6%	PS7.3x

Jan 12

Pharma Mar, S.A. Announces Publication of an Article in the Life Science Alliance Journal, Entitled "Pre-Clinical and Randomized Phase I Studies of Plitidepsin in Adults Hospitalized with Covid-19

PharmaMar has announced the publication of an article in the Life Science Alliance journal, entitled "Pre-clinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19"[1] which includes a study on the in vitro activity of plitidepsin against the main SARS-CoV-2 variants, including the current Omicron variant. According to the final data published in this article, plitidepsin has been shown to have a potent antiviral activity in all variants at very low (nanomolar) concentrations, with a positive in vitro therapeutic index. These studies were led by Dr. Adolfo Garcia-Sastre, Professor in the Department of Microbiology at the Icahn School of Medicine at Mount Sinai, New York, N.Y., USA. Laboratory in vivo studies have also demonstrated a preferential distribution of plitidepsin to lung tissue, which is the organ primarily affected in patients with COVID-19. These studies showed a reduction in viral replication, resulting in a 99% decrease in viral loads in the lung of plitidepsin-treated animals. The article also reviews data from the APLICOV-PC clinical trial, which demonstrated the safety of plitidepsin in patients with COVID-19 requiring hospital admission. The trial met the primary safety endpoint and showed clinical efficacy; in addition the study gathered consistent evidence of a plitidepsin mediated impact on viral load, on inflammatory pathways and on lymphopenia normalization. In this Phase I-II study, 45 patients were enrolled, of whom 86.7% had moderate or severe disease. 41 patients (91%) had pneumonia, 32 (71% of the global sample) of them with bilateral pneumonia. Of note were the data observed in 23 patients with moderate disease, 74% of whom were discharged from hospital within the first week of treatment. These results are the basis for the Phase III NEPTUNO clinical trial that is currently recruiting patients in 17 hospitals in Spain and 9 other countries mainly in Europe and Latin America.

Dec 21

Almirall Announces Results for Atopic Dermatitis in Third Phase 3 Study

Almirall S. A announced Lebrikizumab, an IL-13 inhibitor, significantly improved disease severity when combined with topical corticosteroids (TCS) in people with moderate-to-severe atopic dermatitis (AD) in a third pivotal Phase 3 trial (ADhere) announced by company. Lebrikizumab is a novel, investigational monoclonal antibody (mAb) that binds soluble IL-13 with high affinity, has high bioavailability, a long half-life and blocks IL-13 signaling. In people with AD, the IL-13 protein—a central pathogenic mediator in the disease—is overexpressed, driving multiple aspects of AD pathophysiology by promoting T-helper type 2 (Th2) cell inflammation and resulting in skin barrier dysfunction, itch, infection, flares and hard, thickened areas of skin. The primary endpoints were Investigator Global Assessment (IGA) score of clear (0) or almost clear (1) skin with a reduction of at least two points from baseline and at least a 75% change from baseline in their Eczema Area and Severity Index (EASI) score, both at Week 16. Lebrikizumab in combination with TCS also achieved all key secondary endpoints versus placebo in patients with AD, including skin improvement, itch relief, improvement in interference of itch on sleep, and quality of life. Key secondary endpoints were measured by EASI, the Pruritus Numeric Rating Scale, Sleep-Loss due to Pruritus, and the Dermatology Life Quality Index. Safety results in the 16-week placebo-controlled ADhere study were consistent with the 16-week period of the two monotherapy studies in the lebrikizumab Phase 3 program for AD. The most common adverse events (AEs) included conjunctivitis and headache for lebrikizumab-treated patients. The detailed results from ADhere, along with data from two monotherapy Phase 3 trials, ADvocate 1 and ADvocate 2, are planned for future scientific congresses in 2022. Pending successful completion of the ongoing ADvocate 1 and ADvocate 2 monotherapy trials, Almirall and Eli Lilly and Company intend to begin EU, U.S. and other regulatory submissions next year. Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe. Lilly has exclusive rights for development and commercialization of lebrikizumab in the United States and rest of world outside Europe.

Spanish (IBEX) Healthcare Sector Analysis

Sector Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

CBAV

Investors Shouldn't Overlook Clínica Baviera's (BME:CBAV) Impressive Returns On Capital

GRF

Calculating The Intrinsic Value Of Grifols, S.A. (BME:GRF)

PHM

Pharma Mar, S.A. Announces Publication of an Article in the Life Science Alliance Journal, Entitled "Pre-Clinical and Randomized Phase I Studies of Plitidepsin in Adults Hospitalized with Covid-19

ORY

ORYZON Announces Approval for Serbian Arm of PORTICO, Vafidemstat’s Phase IIb Trial in Borderline Personality Disorder

ROVI

Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?

ALM

Almirall Announces Results for Atopic Dermatitis in Third Phase 3 Study

FAE

Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14

PRM

Upcoming dividend of €0.089 per share

RJF

Insufficient new directors

ADL

Is ADL Bionatur Solutions (BME:ADL) Using Too Much Debt?

EEP

Would Euroespes (BME:EEP) Be Better Off With Less Debt?

PANG

Forecast to breakeven in 2022

ATRY

Atrys Health (BME:ATRY) Might Have The Makings Of A Multi-Bagger